Related Experiment Videos
[Fabry disease (alpha-galactosidase deficiency)]
1Department of Clinical Genetics, Tokyo Metropolitan Institute of Medical Science.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 1, 1995
Summary
Fabry disease, a genetic disorder, stems from alpha-galactosidase deficiency. Researchers identified diverse gene mutations, revealing enzyme activity variations and potential therapeutic strategies.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Context:
- Fabry disease is an X-linked disorder caused by alpha-galactosidase deficiency.
- Patients present with varied clinical forms, including early-onset systemic disease and late-onset cardiomyopathy.
Purpose:
- To investigate the molecular genetic basis of Fabry disease.
- To characterize the biochemical properties of alpha-galactosidase mutants.
- To explore potential therapeutic avenues.
Summary:
- Identified heterogeneous alpha-galactosidase gene mutations, predominantly missense mutations.
- Expressed mutants in COS-1 cells, categorizing them into catalytically inactive and unstable active enzyme groups.
- Demonstrated restoration of unstable enzyme activity in patient cells using substrate analogues.
Impact:
- Provides insights into Fabry disease pathogenesis.
- Highlights the potential for substrate-analogue therapy.
- Advances understanding of enzyme deficiencies and genetic disorders.